Boardable Unveils Fall Release: Engagement Dashboards, New AI Tools & Meeting Insights
New engagement insights, AI-powered meeting support, and enhanced AI controls bring clarity and confidence to every meeting FISHERS, Ind., Nov. 4, 2025 /PRNewswire/... Read more.
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025
Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated... Read more.
Opus IVS™ Unveils Blueprint Copilot – The Industry’s First AI-Enhanced Repair Planning Assistant
Enabling Repair Shops with Intelligent, Real-Time Estimates and Repair Plan Optimization, Built on the ADAS MAP Platform DETROIT, Nov. 4, 2025 /PRNewswire/ —... Read more.
Compugen to Participate in Stifel 2025 Healthcare Conference
HOLON, Israel, Nov. 4, 2025 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer... Read more.
Ezurio Launches the Nitrogen HMI: U.S. Built, Pre-Certified HMI for Industrial, Commercial, and Medical Applications
AKRON, Ohio, Nov. 4, 2025 /PRNewswire/ — Ezurio, a global leader in connectivity and embedded computing, today launches the Nitrogen HMI, a rugged, ready-to-deploy... Read more.
Magnet Biomedicine Appoints Bharat Reddy, Ph.D., as Chief Business Officer
Dr. Reddy brings more than ten years of experience leading biopharma development and strategy to Magnet’s leadership CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/... Read more.
Compass, Inc. Reports Record Third Quarter 2025 Results
Revenue Grew 23.6% YoY; At High-end of Revenue Guide 851 Gross Principal Agents Joined; An All-time High Operating Cash Flow Grew 102% YoY to $75.5 million NEW YORK,... Read more.
Genprex Announces European Patent Office’s Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Adds to the Previously Granted Patents Covering the Use of REQORSA in Combination with Immune Checkpoint Inhibitors Strengthens Patent Estate and Provides Additional... Read more.
Axcelis Announces Financial Results for Third Quarter 2025
Q3 Highlights: Revenue of $213.6 million GAAP Gross Margin of 41.6%, and Non-GAAP Gross Margin of 41.8% GAAP Operating Margin of 11.7% and Non-GAAP Operating Margin... Read more.
Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 /PRNewswire/ — Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a five-year follow-up... Read more.